How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

229 results for

Microdermabrasion

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications

(eg, microdermabrasion, etc.) to facial areas within 8 weeks of the baseline visit. Use of topical retinoids or related agents for the treatment of acne or photoaging in the preceding 6 months. Any dermatological disorder, which in the investigator's opinion, may interfere with the accurate evaluation of the subject's facial appearance. Has known sensitivities or allergies to cosmetics, soaps, fragrances, or any of the ingredients in the test products. Is currently going through menopause

2009 Clinical Trials

182. Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications

participated in other facial studies in the preceding 30 days or other clinical studies in preceding 14 days. Had skin cancer treatment in preceding 12 months. Has damaged skin on facial areas (eg, from sunburn, tattoos, scars). Had any medical procedure (e.g., laser resurfacing, chemical peels, plastic surgery) to facial areas in preceding 12 months. Had any cosmetic procedure (e.g., microdermabrasion, etc.) to facial areas within 8 weeks of the baseline visit. Use of topical retinoids or related agents

2009 Clinical Trials

183. Comparison of Two Botulinum Toxins Type A on Forehead Wrinkles

on the Forehead Wrinkles Severity Scale) on both sides of the forehead Negative urine pregnancy test at the Baseline visit for Subjects of childbearing potential Exclusion Criteria: Subjects with a washout period for procedure(s)/treatment(s) on the forehead less than: Retinoid, microdermabrasion, or prescription level glycolic acid treatments 2 weeks Non-ablative light treatments (e.g. Intense Pulsed Light, light-emitting diodes) 1 month Ablative skin resurfacing Non-ablative dermal treatment for skin

2009 Clinical Trials

184. A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris

supplements and folate are acceptable. Facial procedures (eg, chemical peel, lasers/lights, photodynamic therapy, microdermabrasion, artificial ultraviolet therapy) performed by an esthetician, beautician, physician, nurse, or other practitioner, within the past 4 weeks. Known hypersensitivity or previous allergic reaction to any component(s) or excipient(s) of the study products. Use of any investigational medications or treatments within the past 4 weeks. Treatment with estrogens, including oral

2009 Clinical Trials

185. A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne

, and immunosuppressants such as cyclosporine) as these may impact efficacy assessments. Multivitamins, iron supplements, and folate are acceptable. Facial procedure (eg, blue light, chemical or laser peel, or microdermabrasion) within the past 4 weeks. Require or desire excessive or prolonged exposure to ultraviolet light during the study. Known hypersensitivity or previous allergic reaction to any of the active components of the study product. A significant medical history of or currently immunocompromised. Use

2009 Clinical Trials

186. A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne

of medications that are reported to exacerbate acne (eg, mega-doses of certain vitamins, haloperidol, and immunosuppressants such as cyclosporine) as these may impact efficacy assessments. Multivitamins, iron supplements, and folate are acceptable. Facial procedure (eg, blue light, chemical or laser peel, or microdermabrasion) within the past 4 weeks. Require or desire excessive or prolonged exposure to ultraviolet light during the study. Known hypersensitivity or previous allergic reaction to any

2009 Clinical Trials

187. A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris

of systemic retinoids (eg, isotretinoin) within the past 6 months. Concurrent use of medications known to be photosensitizers because of the possibility of augmented photosensitivity. Use of topical anti-acne medications (eg, benzoyl peroxide, retinoids) within the past 2 weeks. Concomitant use of of facial products such as: abradants, facials, peels containing glycolic or other acids . Facial procedure (eg, chemical or laser peel or microdermabrasion) performed by an esthetician, beautician, physician

2009 Clinical Trials

188. ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients

weeks of initiation of treatment Retinoids, including tazarotene, adapalene, tretinoin, retinol, within 4 weeks of the initiation of treatment. Microdermabrasion, laser ablative treatments, ALA-PDT or chemical peels within 8 weeks of the initiation of treatment. Two or more ALA PDT treatments in the past 6 months Subject has used systemic retinoid therapy within 6 months of the initiation of treatment. Contacts and Locations Go to Information from the National Library of Medicine To learn more about

2009 Clinical Trials

189. Comparison of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminium Garnet (EO QS Nd:YAG) Laser to a Fractionated Laser System

6 months need to be exposed to artificial tanning devices or excessive sunlight during the trial prior treatment with parenteral gold therapy Diabetes Type 1 or 2 does not agree to refrain from any other type of facial skin resurfacing (e.g., microdermabrasion, laser or IPL treatment, chemical peel) or injected fillers/other substances (e.g., Restylane, Botox) that might affect the treatment area for the duration of the study artificial tanning within 1 month (micro)dermabrasion within 3 months

2009 Clinical Trials

190. Azelaic Acid Versus Hydroquinone in Melasma

the last 3 months Exclusion Criteria: if the person has only dermal melasma pregnancy, breastfeeding, a positive pregnancy test in the office or plans to become pregnant a known allergy or sensitivity ot azelaic acid or hydroquinone the use of photosensitizing medications (ex. tetracycline) within 3 months of the study. starting or stopping hormonal medication within 3 months chemical peels, microdermabrasion, or laser treatment within 6 months worsening or improving melasma Contacts and Locations Go

2009 Clinical Trials

191. Proof of Concept Study to Investigate the Recurrence of Acne Post Isotretinoin

the past 2 weeks. Plan to use medications that are reported to exacerbate acne (e.g., mega-doses of certain vitamins, such as vitamin D [> 2000 IU per day] and vitamin B12 [> 1 mg/day], haloperidol, halogens [e.g., iodide and bromide], lithium, hydantoin, and phenobarbital), because these may impact efficacy assessments. Subjects who plan to use multivitamins, iron supplements and folate are acceptable. Had a facial procedure (such as chemical or laser peel, microdermabrasion, blue light treatment, etc

2009 Clinical Trials

192. Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications

studies in preceding 14 days. Had skin cancer treatment in preceding 12 months. Has damaged skin on facial areas (eg, from sunburn, tattoos, scars). Had any medical procedure (eg, laser resurfacing, chemical peels, plastic surgery) to facial areas in preceding 12 months. Had any cosmetic procedure (eg, microdermabrasion, etc.) to facial areas within 8 weeks of the baseline visit. Live in the same household as currently enrolled subjects. Any other condition or factor the investigator or his duly

2009 Clinical Trials

193. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study. (Abstract)

The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study. Recently, topical immunomodulators have been successfully used in monotherapy or in combination with other therapeutic modalities in vitiligo. To determine whether combination pimecrolimus 1% cream and microdermabrasion enhances response time and repigmentation rate in children with vitiligo. Sixty-five children diagnosed with vitiligo (...) enrolled in this randomized placebo-controlled study. Three vitiliginous patches were chosen in each patient. The first lesion was treated by pimecrolimus 1% cream. On the second lesion after doing microdermabrasion on day 1, pimecrolimus 1% cream was applied. On the third lesion placebo was applied. The course of treatment was 10 days. Vitiliginous patches were measured at baseline, day 10, and months 1, 2, and 3. Sixty patients completed the 3-month study period. Clinical response (pigmentation >50

2009 Pediatric dermatology Controlled trial quality: uncertain

194. Molecular analysis of aggressive microdermabrasion in photoaged skin. Full Text available with Trip Pro

Molecular analysis of aggressive microdermabrasion in photoaged skin. To investigate dermal remodeling effects of crystal-free microdermabrasion on photodamaged skin.Biochemical analyses of human skin biopsy specimens following microdermabrasion treatment in vivo.Academic referral center.Volunteer sample of 40 adults, aged 50 to 83 years, with clinically photodamaged forearms. Intervention Focal microdermabrasion treatment with diamond-studded handpieces of varying abrasiveness on photodamaged (...) forearms and serial biopsies at baseline and various times after treatment.Quantitative polymerase chain reaction, immunohistochemistry, and enzyme-linked immunosorbent assay were used to quantify changes in inflammatory, proliferative, and remodeling effectors of normal wound healing. Type I and type III procollagen served as the main outcome marker of dermal remodeling.Coarse-grit microdermabrasion induces a wound healing response characterized by rapid increase in induction of cytokeratin 16

2009 Archives of Dermatology

195. Management of hyperpigmentation in darker racial ethnic groups. (Abstract)

production and degradation. Therapies for these conditions include topical agents and resurfacing procedures. Hydroquinone remains the gold standard of topical agents. Other efficacious agents include kojic acid, azelaic acid, mequinol, and retinoids. Cosmeceutical agents include licorice, arbutin, soy, N-acetyl glucosamine, and niacinamide. Resurfacing procedures that have been used to treat melasma and PIH include chemical peels, microdermabrasion, lasers, and intense pulsed light. These procedures

2009 Seminars in Cutaneous Medicine and Surgery

196. Guidelines for topical photodynamic therapy

, performed in healthy human skin in vivo following microdermabrasion and acetone scrub, showed that two pulsed light sources previously reported in PDT, the PDL and a broadband ?ashlamp ?ltered intense pulsed light (IPL), produced evidence of minimal acti- vation of photosensitizer, with a dramatically smaller photo- dynamic reaction than seen with a conventional continuous wave broadband source. 15 The IPL and PDL sources deliver intense light in periods 130 mm 2 signi?cantly more painful to treat. 195

2008 British Association of Dermatologists

197. Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris

and bromide; lithium; hydantoin; and phenobarbital) as these may impact efficacy assessments. Have had a facial procedure (chemical or laser peel, microdermabrasion, artificial ultraviolet [UV] therapy) performed by an esthetician, beautician, physician, nurse, or other practitioner, within the past 4 weeks. Have a known hypersensitivity or previous allergic reaction to any of the active components, lincomycin, adapalene, clindamycin, BPO, or excipients of the study medication. Employees of a clinical

2008 Clinical Trials

198. Non-cutting Laser Therapy in the Treatment of Acne

into the study. Microdermabrasion or superficial chemical peels at the sites to be treated within 2 months of entry into the study. Subjects with a history of dermabrasion or laser resurfacing at the sites to be treated. Use of topical lipid absorbing substances (Clinac AC) within 2 weeks of entry into the study. Non-compliant subjects. Subjects with a significant medical history or concurrent illness/condition which the investigator(s) feel is not safe for study participation. Subjects using alcohol-based

2005 Clinical Trials

199. Infrared Non-Cutting Laser Therapy for Acne

, and/or be able to attend all of the scheduled appointments during the study. Exclusion Criteria: Oral retinoid (Accutane) use within 1 year of entry into the study. Systemic acne therapies (oral antibiotics) within 4 weeks of entry into the study. Topical acne therapies (retinoids, antibiotics) within 2 weeks of entry into the study. Microdermabrasion or superficial chemical peels at the sites to be treated within 3 months of entry into the study. Subjects with a history of dermabrasion or laser resurfacing

2005 Clinical Trials

200. Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage

with history of laser resurfacing, dermabrasion, medium or deep chemical peel of the face Subjects with diagnosis of skin cancer within 3 months of study entry Subjects who have had superficial chemical peels, exfoliation or microdermabrasion of the face within 3 months of study entry Subjects who have had botulinum toxin for facial rejuvenation within 6 months of study entry and are unwilling to refrain from botulinum toxin treatments during the study Contacts and Locations Go to Information from

2008 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>